Genes (47)
Species: human : 47 | |
Human | SLC22A16 | 85413 | solute carrier family 22 (organic cation/carnitine transporter), member 16 | may be possible to use progestins to increase the response of endometrioid endometrial carcinoma with SLC22A16 expression to adriamycin-based chemotherapeutic regimens | Human | MMP26 | 56547 | matrix metallopeptidase 26 | Increased staining intensity of MMP-26 and TIMP-3 correlated with grade III tumors and MMP-26 and TIMP-4 with the depth of myometrial invasion in tumors histologically characterized as endometrioid adenocarcinoma, clear-cell, and papillary serous carcinoma staged/graded based on FIGO criteria. | Human | ERAP1 | 51752 | endoplasmic reticulum aminopeptidase 1 | Immunohistochemical staining of 58 endometrial endometrioid adenocarcinoma specimens revealed that 37 were A-LAP immunoreactive. | Human | RASSF1 | 11186 | Ras association (RalGDS/AF-6) domain family member 1 | high frequency RASSF1A methylation observed in endometrioid endometrial carcinoma; no association was observed with the development of recurrent disease | Human | IGF2BP3 | 10643 | insulin-like growth factor 2 mRNA binding protein 3 | Expression of IMP3 and p53 may be helpful biomarkers in the distinction of endometrial serous carcinoma from endometrioid adenocarcinoma | Human | WFDC2 | 10406 | WAP four-disulfide core domain 2 | HE4 is a secreted glycoprotein that is overexpressed by serous and endometrioid endometrioid ovarian carcinoma | Human | IQGAP1 | 8826 | IQ motif containing GTPase activating protein 1 | To investigate the alterations in E-cadherin associated with cytoplasmic molecules including alpha-catenin, beta-catenin, gamma-catenin, p120CAS, and IQGAP1 in various endometrial cancers with different degree of differentiation, we examined the localization and expression of E-cadherin and cytoplasmic molecules in 30 cases of both well and poorly differentiated endometrioid adenocarcinomas, using immunofluorescence and immunoblotting techniques. | Human | TP63 | 8626 | tumor protein p63 | [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance] p63, CK 5/6, and CK 14 were respectively expressed in 92.6%, 75.0%, and 52.9% of the squamous cell carcinomas of the lung, 10.2%, 20.0%, and 7.4% of the ductal carcinomas of the breast, 12.9%, 34.4%, and 11.8% of the serous and 25.0%, 0%, and 0% of the endometrioid carcinomas of the ovary. | Human | XRCC2 | 7516 | X-ray repair complementing defective repair in Chinese hamster cells 2 | No XRCC2 coding mutations were identified in the 30 carcinosarcomas, and only one of the fifty MSI-H endometrioid adenocarcinomas had an XRCC2 poly-T tract mutation. | Human | WT1 | 7490 | Wilms tumor 1 | Nuclear WT1 expression is present in a minority of endometrioid ovarian carcinomas | Human | EZR | 7430 | ezrin | Hence, elevated ezrin expression is a new independent prognostic marker in FIGO stage I endometrioid carcinoma, and thus provides further evidence for an important role of ezrin in tumor progression. In endometrioid carcinoma, enhanced ezrin expression correlated with a reduced overall survival in univariate analysis (P=0.041). To assess the importance of ezrin and its associated protein osteopontin for the progression of endometrioid carcinoma in FIGO stage I, we analyzed paraffin-embedded tissue from 164 patients by immunohistochemistry and correlated these data with clinicopathological parameters. Ezrin is de-expressed in endometriosis and endometrioid carcinoma compared with normal uterine epithelium Ezrin expression is related to poor prognosis in FIGO stage I endometrioid carcinomas. | Human | TIMP4 | 7079 | TIMP metallopeptidase inhibitor 4 | Increased staining intensity of MMP-26 and TIMP-3 correlated with grade III tumors and MMP-26 and TIMP-4 with the depth of myometrial invasion in tumors histologically characterized as endometrioid adenocarcinoma, clear-cell, and papillary serous carcinoma staged/graded based on FIGO criteria. | Human | TIMP3 | 7078 | TIMP metallopeptidase inhibitor 3 | Increased staining intensity of MMP-26 and TIMP-3 correlated with grade III tumors and MMP-26 and TIMP-4 with the depth of myometrial invasion in tumors histologically characterized as endometrioid adenocarcinoma, clear-cell, and papillary serous carcinoma staged/graded based on FIGO criteria. | Human | TIMP2 | 7077 | TIMP metallopeptidase inhibitor 2 | METHODS: MMP-2, MMP-2 activator, MT1-MMP, and its inhibitor (TIMP-2) were immunostained in 84 primary epithelial ovarian carcinomas (EOCs) (35 endometrioid adenocarcinomas [ECs] and 49 serous adenocarcinomas [SCs]). | Human | TFF3 | 7033 | trefoil factor 3 (intestinal) | Patients harbouring G3-endometrioid endometrial carcinomas had significantly higher TFF3 serum concentration by ELISA when compared with healthy patients or patients harbouring endometrial hyperplasia | Human | TFF1 | 7031 | trefoil factor 1 | All six cases of endometrioid carcinoma, together with control cases of benign prostatic hypertrophy (BPH) and ordinary adenocarcinoma of the prostate had unequivocal diffuse positive staining for PSA and similar reactivity to ER-D5 and PS2. | Human | TERT | 7015 | telomerase reverse transcriptase | telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium | Human | RCVRN | 5957 | recoverin | Cytoplasmic immunoreactivity for recoverin and hsc 70 was observed in endometrioid carcinoma cells. | Human | PTEN | 5728 | phosphatase and tensin homolog | We conclude that most frequently occurring mutations in the PTEN gene may be a key event for the tumorigenesis of endometrioid endometrial carcinomas PTEN mutations were significantly correlated with uterine endometrioid carcinoma compared with atypical hyperplasia | Human | KLK10 | 5655 | kallikrein-related peptidase 10 | RESULTS: Kallikrein 10 gene expression levels were significantly higher in uterine serous papillary carcinoma when compared with normal endometrial cell biopsies (mean copy number by real time polymerase chain reaction = 743 versus 1.4; uterine serous papillary carcinoma versus endometrioid carcinoma: P _lt_ .02). In contrast, no kallikrein 10 secretion was detectable in primary endometrioid carcinomas. Finally, kallikrein 10 concentration in 75 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 21 women with endometrioid carcinomas, and 12 uterine serous papillary carcinoma patients was studied. Kallikrein 10 serum and plasma concentrations (microg/L; mean +/- SEM) among normal healthy females (0.6 +/- 0.04), patients with benign diseases (0.6 +/- 0.06), and patients with endometrioid carcinomas (0.7 +/- 0.06) were not significantly different. In contrast, serum and plasma kallikrein 10 values in uterine serous papillary carcinoma patients (1.2 +/- 0.1) were significantly higher than those in the non-cancer group (P = .002), benign group (P = .002), and endometrioid carcinoma patients (P = .005). Secretion of kallikrein 10 protein by 10 primary tumor cultures including 3 uterine serous papillary carcinomas, 2 endometrioid carcinomas, and 5 ovarian serous papillary tumors was measured using a sensitive ELISA. | Human | KLK6 | 5653 | kallikrein-related peptidase 6 | In contrast, no hK6 secretion was detectable in primary endometrioid carcinoma and cervical cancer cultures. hK6 serum and plasma concentrations (mean +/- SE) among normal healthy females (2.7 +/- 0.2 mug/L), patients with benign diseases (2.4 +/- 0.2 mug/L), and patients with endometrioid carcinoma (2.6 +/- 0.2 mug/L) were not significantly different. PURPOSE: The discovery of novel biomarkers might greatly contribute to improve clinical management and outcomes in uterine serous papillary carcinoma (USPC), a highly aggressive variant of endometrial cancer.EXPERIMENTAL DESIGN: Human kallikrein 6 (hK6) gene expression levels were evaluated in 29 snap-frozen endometrial biopsies, including 13 USPC, 13 endometrioid carcinomas, and 3 normal endometrial cells by real-time PCR. Secretion of hK6 protein by 14 tumor cultures, including 3 USPC, 3 endometrioid carcinoma, 5 ovarian serous papillary carcinoma, and 3 cervical cancers, was measured using a sensitive ELISA. hK6 may represent a novel biomarker for USPC for monitoring early disease recurrence and response to therapy. In contrast, serum and plasma hK6 values in USPC patients (6.1 +/- 1.1) were significantly higher than those in the noncancer group (P = 0.006), benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005). In contrast, serum and plasma hK6 values in USPC patients (6.1 +/- 1.1) were significantly higher than those in the noncancer group (P = 0.006), benign group (P = 0.003), and endometrioid carcinoma patients (P = 0.005).CONCLUSIONS: hK6 is highly expressed in USPC and is released in the plasma and serum of USPC patients. Finally, hK6 concentration in 79 serum and plasma samples from 22 healthy women, 20 women with benign diseases, 20 women with endometrioid carcinoma, and 17 USPC patients was studied.RESULTS: hK6 gene expression levels were significantly higher in USPC when compared with endometrioid carcinoma (mean copy number by real-time PCR, 1,927 versus 239, USPC versus endometrioid carcinoma; P < 0.01). | Human | PGR | 5241 | progesterone receptor | Loss or absence of progesterone receptor expression is associated with endometrioid endometrial carcinoma | Human | OVGP1 | 5016 | oviductal glycoprotein 1, 120kDa | OGP was found in 7 of 14 (50%) borderline and 9 of 15 (60%) malignant mucinous ovarian tumors and in 10 of 39 (26%) endometrioid adenocarcinomas. | Human | NOS3 | 4846 | nitric oxide synthase 3 (endothelial cell) | No apparent correlation was found between ecNOS expression and tumor stage, grade, extension to the lower uterine segment or cervix, nodal or distant metastases, recurrence, or final patient status among patients with endometrioid adenocarcinomas. | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | The current study on endometrioid carcinoma was undertaken to examine the status of two tumor suppressor genes that frequently have been found to be altered in human malignancies (the p53 gene and the retinoblastoma [Rb] gene) and to examine the status of the candidate metastatic suppressor gene, nm23-H1. METHODS. |
|